Pharmaceutical Executive-12-01-2010

After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation

After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation

A small company shows how it can play a major role in a relatively short time frame

How to achieve distribution diversification in a small market

With a fiercely competitive spirit and grand ambitions that reach far beyond Taiwan, Standard is showing that it is far from the middle-of-the-road company its name implies

The simpler the explanation of a disorder and its treatment, the better able a patient is to take proper care of himself

Being strategic-and applying data tools effectively- will go along way in helping to produce analytics that drive sales

Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your prouct into consumers' lives in a series of personal, non-invasive ways

The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica

The end of anther year is an appropriate time to highlight the march of time-and the transitions that accompany it

Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance

Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine

Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office

42 of the best new drugs in development–or parked at the FDA

Pharma sets the pace for China's ambitious new innovation agenda

The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?

Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend

Pharm Exec's Pipeline Report 2018